Your search for "parasiticides" return 13 results.
Ceva attracts strong investor support for 4th LMBO and returns to double-digit growth in first 6 months of 2014
14% growth pushes sales beyond 600 M€ for first time
Double-digit growth confirms long term upward trend
Twin pillar strategy of combining internal and external growth opportunities drives further global expansion
Company continues to expand its North American operations with entry into Canada.
2010 results demonstrate global ability to generate sales and earnings
LENEXA, Kan.— Ceva, a global veterinary pharmaceutical group, is pleased to announce the company has entered into an agreement with Sumitomo Corporation of America, and Sumitomo Corporation, to acquir...
Among the other therapeutic fields in which the Ceva Group proposes a significant offering, we will mention:ReproductionGALASTOP (Cabergoline) GALASTOP is a prolactin inhibitor used to treat lactatio...
Alongside the Ceva Group’s recognised fields of expertise in vaccines, control of reproduction or antibiotic therapy, it also proposes complementary products specifically adapted to swine farming
Ceva is a key partner for the swine sector, thanks to a broad range of veterinary products providing the right responses to the sanitary and zootechnical objectives of modern swine farming.